Literature DB >> 3789695

Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis.

M J Smith, L O White, H Bowyer, J Willis, M E Hodson, J C Batten.   

Abstract

Levels of ciprofloxacin in serum and sputum were studied for eight patients with cystic fibrosis who were infected with Pseudomonas aeruginosa. Patients were studied in a steady state on a dosage of 500 mg every 8 h. Peak levels in serum ranged from 1.27 to 5.6 mg/liter (mean, 3.16 +/- 1.27), and absorption was rapid, the time to peak concentration ranging from 0.5 to 3.0 h (mean, 1.5 +/- 0.9). The antibiotic penetrated sputum well, achieving areas under the curve of approximately 46% of those obtained in serum.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3789695      PMCID: PMC176492          DOI: 10.1128/AAC.30.4.614

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

2.  Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis.

Authors:  A Penketh; M E Hodson; H Gaya; J C Batten
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

3.  In-vitro studies with ciprofloxacin, a new 4-quinolone compound.

Authors:  D S Reeves; M J Bywater; H A Holt; L O White
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

4.  Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis.

Authors:  A R Penketh; M E Hodson; J C Batten
Journal:  Br J Dis Chest       Date:  1983-04

5.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

  5 in total
  21 in total

1.  Survey: calculation of the characteristics of oral diffusion-controlled release dosage forms related to the drug.

Authors:  I D Rosca; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

2.  Calculation of the antibiotic level in the lung tissue and bronchial secretion with an oral controlled-release dosage form.

Authors:  M Saïdna; E M Ouriemchi; J M Vergnaud
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

Review 3.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

Review 4.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of inhaled antimicrobials.

Authors:  Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

6.  Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin.

Authors:  U B Schaad; J Wedgwood-Krucko; K Guenin; U Buehlmann; R Kraemer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

7.  Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.

Authors:  P Saux; C Martin; M N Mallet; L Papazian; B Bruguerolle; P De Micco; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 8.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

9.  Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.

Authors:  H Tomioka; H Saito; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Authors:  Heino Stass; Johannes Nagelschmitz; Stefan Willmann; Heinz Delesen; Abhishek Gupta; Sybille Baumann
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.